Emerald Bioscience to Present at the 9th Annual Glaucoma 360 New Horizons Forum and BIO CEO & Investor Forum
January 30, 2020 08:30 ET
|
Emerald Bioscience, Inc.
Long Beach, CA, Jan. 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical...
Emerald Bioscience Announces $2.0 Million Registered Direct Offering
November 21, 2019 09:12 ET
|
Emerald Bioscience, Inc.
Long Beach, CA, Nov. 21, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald”), a biopharmaceutical company focused on bioengineered cannabinoid-based...
Emerald Bioscience’s NB1111 Demonstrates Superiority in Lowering Intraocular Pressure Compared to Global Standard of Care Glaucoma Treatment in Preclinical Model
October 15, 2019 08:35 ET
|
Emerald Bioscience, Inc.
LONG BEACH, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global...
Glauconix Presents Data Validating Impact of Emerald Bioscience’s Prodrug on the Ocular Endocannabinoid System in Glaucoma
October 15, 2019 08:30 ET
|
Emerald Bioscience, Inc.
Study Points to Unique Link Between the Endocannabinoid System and the Inflammatory Cascade in the Eye LONG BEACH, CA, Oct. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc....
Emerald Bioscience Appoints Chief Medical Officer and Executive Director, Clinical Operations
August 26, 2019 08:30 ET
|
Emerald Bioscience, Inc.
Long Beach, CA, Aug. 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical...
Emerald Bioscience to Present at the 9th Annual LD Micro Invitational
June 03, 2019 08:00 ET
|
Emerald Bioscience, Inc.
LONG BEACH, CA, June 03, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to...
Emerald Bioscience to Participate at the CannaStocks 2019 Q1 Investor Conference
May 13, 2019 08:00 ET
|
Emerald Bioscience, Inc.
LONG BEACH, CA , May 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical...
Emerald Bioscience, Inc. Announces DEA Decision that its Proprietary Cannabidiol Analog is not a Regulated Chemical or Controlled Substance Under Controlled Substances Act
April 01, 2019 07:30 ET
|
Emerald Bioscience, Inc.
LONG BEACH, CA, April 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on developing bioengineered cannabinoid-based...
Nemus Bioscience, Inc. Changes Name to Emerald Bioscience, Inc. and Provides Update of Recent Research Accomplishments
March 25, 2019 08:00 ET
|
Emerald Bioscience, Inc.
Name Change Reflects Company’s Focus on Advancing Cannabinoid-Based Therapeutics as a Member of the Emerald Group Company to Trade on OTCQB Under Ticker EMBI at Market Open March 25, 2019 ...